skin came off in chunk/ felt like it got bad on hands; red all over; broke out in rash that travel down to patient's body; COVID-19; This spontaneous case was reported by a patient and describes the occurrence of SKIN EXFOLIATION (skin came off in chunk/ felt like it got bad on hands), ERYTHEMA (red all over), COVID-19 (COVID-19) and RASH (broke out in rash that travel down to patient's body) in a 66-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.    Co-suspect product included non-company product ADALIMUMAB (HUMIRA) solution for injection for Platelet rich plasma therapy.    No Medical History information was reported.   On 22-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 22-Mar-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient started ADALIMUMAB (HUMIRA) (Subcutaneous) at an unspecified dose. In 2021, the patient experienced COVID-19 (COVID-19). On an unknown date, the patient experienced SKIN EXFOLIATION (skin came off in chunk/ felt like it got bad on hands), ERYTHEMA (red all over) and RASH (broke out in rash that travel down to patient's body). At the time of the report, SKIN EXFOLIATION (skin came off in chunk/ felt like it got bad on hands) and ERYTHEMA (red all over) had not resolved and COVID-19 (COVID-19) and RASH (broke out in rash that travel down to patient's body) outcome was unknown.            No concomitant drug reported.  It was unknown if patient was enrolled in a COVID-19 vaccine trial. The reporter's causality for the event of patient was red all over and skin came off in chunks/ felt like it got bad on hands unknown onset and patient red all over skin came off in chunks/felt like it got bad on hands unknown onset with Humira (adalimumab) was a reasonable possibility (Probable). The reporter's causality for the event of COVID and broke out in rash that traveled down patient's body was not provided. The formulation for co-suspect product Humira was reported as Solution for injection in pre-filled syringe.  No treatment information was provided by the reporter.  COMPANY COMMENT: This is an spontaneous case concerning a 66-years-old male patient with medical history of co-suspect Humira medication treatment who experienced the unexpected events of Covid-19, skin exfoliation, erythema and other expected event in the context of the  2nd. dose of  mRNA-1273 vaccine.  The medical history of Humira remains a confounder for skin exfoliation, erythema events. The benefit-risk relationship of mRNA-1273 vaccine is not affected by this report.; Sender's Comments: COMPANY COMMENT: This is an spontaneous case concerning a 66-years-old male patient with   medical history of co-suspect Humira medication treatment who experienced the unexpected events of Covid-19, skin exfoliation, erythema and other expected event in the context of the  2nd. dose of  mRNA-1273 vaccine.  The medical history of Humira remains a confounder for skin exfoliation, erythema events. The benefit-risk relationship of mRNA-1273 vaccine is not affected by this report.